The study tackled a persistent problem in microbiome science. Most gut microbiota studies of psychiatric and addictive disorders have been conducted in single, relatively homogeneous populations, which makes it difficult to know whether observed microbial changes are genuinely tied to the disease or merely reflect the dietary habits, environment, or genetic background of one particular group. Ethnicity is known to shape the gut microbiome substantially, so a microbial alteration seen in one population might simply be noise when viewed against a different genetic and cultural backdrop. To address this, the team designed a multi-center study recruiting patients from two hospitals in different regions of China, one serving a predominantly Han population and the other serving Uyghur participants, whose traditional dietary patterns and genetic ancestry differ considerably from those of Han Chinese.

Methodologically, the researchers went beyond the 16S ribosomal RNA surveys that dominate much of the microbiome literature. They used shotgun metagenomic sequencing, a technique in which all microbial DNA in a stool sample is fragmented and sequenced directly, allowing researchers to identify not only which bacterial species are present but also which functional genes and metabolic pathways they carry. This higher-resolution approach matters because two microbial communities can look similar at the genus level while differing dramatically in what they are actually doing. The team constructed an Integrated Gene Catalog from their sequencing data and compared taxonomic composition and functional pathways between patients with alcohol use disorder and matched healthy controls within each ethnic group, and then across both groups simultaneously.

To ensure that the observed differences were attributable to the disorder itself rather than confounding variables such as age, body mass index, or co-occurring health conditions, the investigators applied propensity score matching, a statistical technique borrowed from epidemiology that pairs patients and controls on measurable covariates. Differences in microbial community structure were tested with principal coordinates analysis and permutational multivariate analysis of variance, while differential abundance of individual species and pathways was assessed with statistical tools including the Linear Discriminant Analysis Effect Size method and the Statistical Analysis of Metagenomic Profiles, with false discovery rate correction applied to guard against spurious findings. The study was approved by the ethics committee of the Second Xiangya Hospital and conducted under the Declaration of Helsinki, with written informed consent from all participants.

The results confirmed that active alcohol use disorder is associated with significant disruption of the gut microbiota in both populations. When the researchers visualized the overall microbial communities, patients with the disorder clustered apart from healthy controls within each ethnic group, indicating that the disease leaves a detectable imprint on community structure. Yet the more striking finding emerged when the two patient groups were compared with each other. Despite distinct baseline ethnic profiles between Han and Uyghur healthy individuals, a robust shared signature appeared under active alcohol use disorder, characterized by the depletion of specific commensal taxa, particularly bacteria known to produce short-chain fatty acids.

Short-chain fatty acids, including acetate, propionate, and butyrate, are the metabolic currency of a healthy gut. These molecules are manufactured by certain commensal bacteria as they ferment dietary fiber, and they serve as the primary energy source for the cells lining the colon, help maintain the integrity of the intestinal barrier, modulate immune signaling, and communicate with the nervous system through the gut-brain axis. A consistent loss of short-chain fatty acid producers is therefore more than a taxonomic curiosity; it suggests a functional erosion of the gut’s capacity to regulate inflammation and barrier function, processes increasingly implicated in the systemic and neural consequences of heavy alcohol consumption.

At the species level, the convergence was remarkably specific. Four beneficial commensals were consistently and significantly depleted in both the Han and Uyghur patient groups, with statistical significance surviving false discovery rate correction. These were Fusicatenibacter saccharivorans, Eubacterium hallii, Ruminococcus torques, and Dorea formicigenerans. Each of these organisms is regarded as a health-associated member of the intestinal community. Eubacterium hallii, for example, is a well-studied producer of butyrate and propionate, while Fusicatenibacter saccharivorans has been linked to anti-inflammatory activity in prior research. The fact that the same four species dropped out in parallel across two ancestrally and culturally distinct cohorts suggests that chronic alcohol exposure exerts a selective pressure on the gut ecosystem that overrides baseline ethnic differences.

The functional analysis deepened the picture further. When the researchers examined microbial metabolic pathways rather than species identities, they found convergent functional disturbances shared by both patient groups. Core microbial DNA replication pathways were depleted, as were DNA repair mechanisms, specifically mismatch repair and homologous recombination, and the protein translation pathway of aminoacyl-tRNA biosynthesis. These are fundamental housekeeping functions of microbial life, and their consistent reduction points to a state of broad metabolic and replicative stress within the gut microbial community of patients with active alcohol use disorder. Alcohol and its metabolite acetaldehyde are known genotoxic agents, and the observed depletion of microbial DNA maintenance machinery may reflect direct damage to microbial genomes or a shift in community composition away from organisms that invest heavily in genome upkeep.

The authors are careful to frame these findings as hypothesis-generating rather than definitive. The study was cross-sectional, meaning it captured a snapshot of the gut microbiota at a single point in time, so it cannot determine whether the microbial depletions are a cause of alcohol use disorder, a consequence of chronic drinking, or a mixture of both. The cohorts were composed of male participants, which limits generalizability to women. Longitudinal studies that follow individuals over time, ideally through periods of drinking and abstinence, will be needed to establish the direction of the relationship and to test whether the depleted commensals recover with sobriety. The researchers explicitly position the consistent loss of short-chain fatty acid producers as candidate features for future longitudinal validation and mechanistic exploration.

Even so, the implications are considerable. If the shared microbial signature holds up in larger and more diverse cohorts, it could inform the development of microbiome-based biomarkers for alcohol use disorder, complementing clinical and psychological assessment. It also raises the possibility of therapeutic intervention. Fecal microbiota transplantation and targeted probiotic or dietary strategies aimed at restoring short-chain fatty acid producers are already being explored for other conditions, and the gut-liver axis, the bidirectional communication between intestinal microbes and hepatic physiology, is a central pathway in alcoholic liver disease. Restoring a depleted commensal community might not treat addiction itself, but it could mitigate some of the intestinal and systemic damage that accompanies heavy drinking. By demonstrating that the same microbial casualties appear in two very different populations, this study moves the field a step closer to distinguishing the genuine biological footprint of alcohol use disorder from the background noise of human diversity, and it underscores a simple message that is resonating across modern medicine: to understand disorders of the brain, researchers increasingly need to look at the gut.

Subject of Research: Shared gut microbiota alterations in Han and Uyghur patients with alcohol use disorder

Article Title: Shared microbial alterations in Han and Uyghur patients with alcohol use disorder

Article References: Ding, Q., Hu, H., Xu, X., Chen, T., & Zhang, X. (2026). Shared microbial alterations in Han and Uyghur patients with alcohol use disorder. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08752-0

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08752-0

Keywords: alcohol use disorder, gut microbiota, shotgun metagenomics, short-chain fatty acids, dysbiosis, gut-brain axis, gut-liver axis, ethnicity, microbiome, psychiatry, commensal bacteria, DNA repair pathways

The work addresses a gap that has shaped the trajectory of genome engineering for more than a decade. Since the advent of programmable nucleases, researchers have been able to direct double-strand breaks to almost any chosen sequence, and cellular repair machinery can sometimes stitch in a new DNA cassette at the break site. But that approach leans on the cell’s own repair pathways, which are error-prone, unpredictable and often disabling to the very sequences scientists want to insert. Broken DNA is dangerous DNA, and cells treat integration events as injuries to be patched rather than as opportunities for precise reconstruction.

Prime editing, first described in 2019, took a fundamentally different route. Rather than cutting both strands of the DNA double helix, a prime editor pairs a Cas9 nickase — an engineered enzyme that cuts only one strand — with an engineered reverse transcriptase. The editing instructions are carried on a prime editing guide RNA, or pegRNA, which both locates the target site and encodes the new genetic information the reverse transcriptase should write into the nicked strand. Because the process avoids double-strand breaks and does not require an additional donor DNA template supplied in bulk, prime editing has proven remarkably clean for small substitutions, insertions and deletions.

Where prime editing has historically faltered, however, is scale. The reverse transcriptase copies a sequence encoded within the pegRNA itself, and practical constraints on RNA length, delivery and synthesis efficiency have limited the size of the DNA payload that a single prime-editing event can install. For applications in which a functional gene, a large regulatory element or a multi-kilobase cassette must be placed at a defined genomic address, the technology’s ceiling has been a persistent frustration. Complementary systems — including CRISPR-associated transposases and integrase-based platforms — can move larger cargoes, but they typically bring their own constraints on target-site selection, orientation and cargo compatibility.

The new study, led by researchers working at the interface of protein engineering and genome technology, tackles the size problem by rethinking how the donor DNA participates in the reaction. In the reported strategy, termed donor-directed annealing, the genetic cargo is carried on a separate donor molecule rather than being encoded within the pegRNA. The prime editor still performs its characteristic task of opening the target site and synthesizing an exposed stretch of new DNA on the nicked strand, but that newly synthesized sequence is designed to serve as a molecular landing pad. Once exposed, it is complementary to sequences at the end of the donor fragment, and the two single-stranded regions find each other and anneal, drawing the donor cargo into the editing site.

The elegance of the design lies in what happens next. Cellular DNA repair enzymes process the annealed intermediate, ligating the donor fragment into the genome through the natural resolution of the flap-like structure that the prime editor has created. Because the specificity of the event is dictated by sequence complementarity between the editor-generated overhang and the donor terminus, the cell is never asked to recognize a double-strand break or to improvise an end-joining reaction. The authors report that this mechanism allows fragments substantially larger than the payloads accessible to conventional prime editing to be incorporated at defined loci, with precision determined largely by the programmed overlap rather than by stochastic cellular repair.

From a biochemical standpoint, donor-directed annealing converts what has been an intramolecular copying reaction into a hybridization-guided assembly step. Conventional prime editing is, in essence, a controlled form of DNA synthesis: the pegRNA templates every base that the reverse transcriptase installs. The new method retains that templated synthesis for a short anchoring sequence but delegates the bulk of the payload to a separate donor, which can be produced synthetically or by standard cloning at lengths far beyond what a pegRNA can encode. The trade-off is that the donor and the pegRNA must be co-delivered and their sequences coordinated, but the payoff is a system in which cargo size is no longer bound to the physical limits of the guide RNA.

The practical implications extend across both research and therapeutic arenas. In basic biology, the ability to drop large regulatory modules, reporter constructs or engineered gene circuits into precise genomic contexts would simplify experiments that currently require laborious screening of random integration events. In medicine, many inherited disorders are caused by mutations in genes that are too large, too structurally complex or too mutationally diverse to be addressed base by base. Delivering a corrected copy of a gene, or a functional cDNA, into its native locus under the control of endogenous regulatory elements — rather than scattering it randomly through the genome as viral vector gene therapy does — remains the aspirational gold standard, and integration strategies of this kind are among the most credible paths toward it.

The reported system also speaks to a recurring theme in the genome-editing literature: the value of avoiding double-strand breaks altogether. Studies across multiple cell types have associated double-strand-break-based editing with p53 activation, chromosomal rearrangements and large unintended deletions, concerns that are particularly acute for ex vivo cell therapies and in vivo applications alike. By building integration on a nicking enzyme and sequence-programmed annealing rather than on blunt-ended break repair, the approach aligns with the field’s broader movement toward editing chemistries that leave the genome’s integrity machinery largely undisturbed.

As with any genome-engineering advance, several questions will shape how the technique matures. The efficiency of integration across different genomic loci, cell types and species will need systematic mapping; cargo lengths will have practical ceilings set by delivery vehicles rather than by chemistry; and off-target activity — a concern for any nuclease-fusion system — will require careful characterization at both the sequence and chromosomal level. The study’s authors report encouraging precision at the sites they examined, and the strategy’s dependence on designed sequence complementarity offers a built-in specificity checkpoint that many integration methods lack. Independent replication and optimization in therapeutically relevant primary cells will be the next milestones.

What the work illustrates most clearly is how quickly the conceptual boundaries of genome editing continue to move. In barely a decade, the field has progressed from cutting DNA at chosen addresses, to rewriting individual letters of the genetic code, to contemplating the programmed installation of whole functional modules at will. Donor-directed annealing extends prime editing’s core strengths — precision, minimized DNA damage and programmability — into a size regime that those strengths had not previously reached. If the method’s efficiency and reliability hold up as it is tested more broadly, large-fragment insertion could shift from a heroic, low-yield exercise to a routine operation in the genome engineer’s toolkit, with consequences for drug discovery, synthetic biology and, ultimately, the treatment of diseases that small edits alone cannot fix.

Subject of Research: Precise integration of large DNA fragments into genomic target sites using prime editing with donor-directed annealing

Article Title: Precise genomic integration of large DNA fragments by donor-directed annealing using prime editing

Article References: Jung, H., Jeong, B., Kim, Y.-W., Jung, C., Lee, S., Uhm, H., Kim, H., Oh, Y. E., Park, Y., Lee, Y., Kang, M., Im, H. W., Kim, D., Lee, S., Kim, Y., Choi, K., & Bae, S. (2026). Precise genomic integration of large DNA fragments by donor-directed annealing using prime editing. Nature Biotechnology. https://doi.org/10.1038/s41587-026-03301-2

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03301-2

Keywords: prime editing, genome editing, CRISPR, gene therapy, DNA integration, pegRNA, reverse transcriptase, Cas9 nickase, large DNA fragments, donor-directed annealing, biotechnology, genetic engineering

ATRX has occupied a special place in chromatin biology for more than two decades. Mutations in the ATRX gene cause alpha-thalassemia/mental retardation X-linked syndrome, a condition marked by severe intellectual disability, anemia, and characteristic changes in DNA methylation patterns. The protein belongs to the SWI/SNF family of ATP-dependent chromatin remodelers and carries a conserved ADD domain that reads chemical tags on histone H3, allowing ATRX to home in on specific regions of the genome. Early work established that ATRX binds highly repetitive, difficult-to-copy DNA sequences—tandem repeats, ribosomal DNA, pericentromeric heterochromatin, and telomeres—suggesting that its cellular job is to smooth out the rough patches of the genome. But precisely how ATRX accomplishes this, and which partner molecules divide the labor with it, has remained stubbornly unresolved. The new study tackles that question head-on by separating ATRX’s activities into discrete, mechanistically distinguishable functions and then testing how each one interfaces with the 9-1-1 and CST complexes.

The 9-1-1 complex, a heterotrimeric ring structurally related to the sliding clamps that tether DNA polymerases, is loaded onto recessed DNA junctions during replication stress. It functions as a platform for recruiting factors that restart stalled forks, enforce cell-cycle checkpoints, and fill in gaps left behind when the replication fork runs into trouble. The CST complex—composed of CTC1, STN1, and TEN1—was originally characterized as a helper for telomere maintenance, facilitating the synthesis of telomeric repeats by polymerase alpha-primase and protecting chromosome ends from inappropriate DNA damage responses. In recent years, however, CST has emerged as a genome-wide player: it fills in so-called C-strands at telomeres, assists with the completion of lagging-strand synthesis at difficult sites throughout the genome, and restarts replication after forks collapse. Because ATRX-deficient cells show hallmark signs of replication failure at telomeres and other repetitive regions, the possibility that ATRX and these two complexes operate in a common pathway was an obvious but untested hypothesis.

Using a combination of genetic epistasis experiments, live-cell imaging, and biochemical assays, the research team systematically perturbed ATRX, components of the 9-1-1 complex, and members of CST, then examined how these perturbations affected the cells’ ability to complete DNA synthesis at fragile genomic sites. The results reveal a layered defense architecture. One ATRX function—its capacity to remodel nucleosomes at problematic loci—acts upstream, preventing replication forks from stalling in the first place. A second, ATPase-independent function operates after fork trouble begins, cooperating with 9-1-1 to promote the resumption of DNA synthesis and the suppression of DNA damage signaling in regions that remain difficult to traverse. When either ATRX or the 9-1-1 clamp is disabled, cells accumulate under-replicated DNA and chromosome abnormalities that are characteristic of replication catastrophe, and the two defects are not additive—a genetic signature indicating that ATRX and 9-1-1 function in the same pathway rather than in parallel ones.

The telomere story is particularly striking. Telomeres terminate in single-stranded overhangs that must be filled in to form complete double-stranded DNA; failure to do so triggers chromosome-end fusions and catastrophic genome rearrangements. CST is the canonical executor of this fill-in reaction, recruiting and stimulating polymerase alpha-primase at chromosome ends. The new work shows that ATRX does not duplicate this function but rather supports it: in cells lacking ATRX, CST fails to complete its job efficiently at telomeres, leaving persistent single-stranded tails and exposing chromosome ends to aberrant repair. Restoring ATRX, or specifically rescuing its chromatin-remodeling activity at telomeric repeats, restores proper CST-dependent fill-in and eliminates the telomere dysfunction markers that otherwise accumulate. The authors present evidence that ATRX’s remodeling of the repetitive nucleosome arrays at telomeres creates a chromatin environment in which CST and the polymerase machinery can access their substrate—essentially clearing the molecular clutter that would otherwise block the repair crew.

This division of labor has significant implications for how scientists understand the genome-wide consequences of ATRX loss in human disease. ATRX syndrome patients carry mutations scattered across the protein, and previous studies had struggled to connect the dots between ATRX’s in vitro biochemical activities and the specific cellular phenotypes seen in patients. By demonstrating that distinct ATRX functions—nucleosome remodeling, checkpoint cooperation through 9-1-1, and CST-dependent telomere maintenance—can be genetically separated and mechanistically ordered, the study provides a framework for interpreting patient mutations. It suggests that different clinical presentations might correspond to different degrees of impairment in these parallel arms of ATRX function, opening the door to genotype-specific predictions about disease severity and, potentially, to therapeutic strategies that compensate for one defective arm by strengthening another.

The research also reframes a long-standing puzzle in telomere biology. Certain inherited disorders—collectively known as telomere biology disorders, including Coats plus syndrome and dyskeratosis congenita—arise from mutations in CST components themselves. The finding that ATRX acts upstream of CST in telomere maintenance suggests a functional connection between ATRX syndrome and these CST-linked diseases, even though the clinical symptoms differ. Both classes of patients show signs of shortened or dysfunctional telomeres, defective DNA replication at chromosome ends, and heightened sensitivity to replication stress. The new study provides a mechanistic bridge: it is the coordinated action of ATRX, 9-1-1, and CST that ensures telomeres are replicated and completed properly, and disruption at any point in this triad produces overlapping—but not identical—forms of genome instability.

From a broader perspective, the work speaks to one of the central organizing principles of modern genome biology: that the cell’s response to replication stress is not a single pathway but a combinatorial network, in which dedicated factors specialize in different classes of difficult DNA and in different stages of the replication process. ATRX, 9-1-1, and CST represent three nodes of this network—chromatin remodeling, fork restart, and DNA synthesis completion, respectively—and the new data show that they are not merely co-present at problematic sites but actively interdependent. Removal of any one node increases the burden on the others and, when that burden exceeds a threshold, converts a recoverable stall into an unrecoverable fork collapse. This kind of systems-level understanding is increasingly viewed as essential for predicting how cells fail under stress and how such failures propagate into disease.

The implications extend to cancer biology as well. ATRX is mutated or silenced in a substantial fraction of tumors, particularly gliomas, pancreatic neuroendocrine tumors, and certain sarcomas. These tumors frequently rely on an alternative mechanism of telomere maintenance, called alternative lengthening of telomeres or ALT, which uses homologous recombination to extend chromosome ends without the enzyme telomerase. The loss of ATRX is one of the most reliable predictors of ALT activation in clinical pathology, and the new findings provide a plausible mechanistic explanation: without ATRX to safeguard telomere replication and support CST-dependent fill-in, surviving cells are pushed toward recombination-based strategies to keep their chromosome ends intact. Understanding the precise molecular handoffs between ATRX, 9-1-1, and CST may therefore reveal vulnerabilities in ALT-positive cancers that could be exploited therapeutically, for instance by targeting the recombinational pathways that ATRX-deficient tumors depend upon.

The study, published in Nature Structural & Molecular Biology, represents a substantial step forward in resolving the functional anatomy of ATRX and situating it within the larger machinery that guards the genome during DNA replication. It replaces a broad and somewhat vague notion—ATRX protects difficult DNA—with a concrete, mechanistic model: ATRX remodels chromatin to prevent replication problems, cooperates with 9-1-1 to recover from the problems that still arise, and enables CST to complete the final steps of DNA synthesis at telomeres and other lagging-strand regions. As genome instability remains a driving force in cancer, aging, and inherited disease, dissecting these molecular partnerships is not merely an academic exercise; it is a necessary step toward interventions that can either prevent or exploit the failures of genome maintenance. The ATRX–9-1-1–CST axis now stands as one of the clearest examples of how the cell choreographs its replication machinery across the most treacherous stretches of the human genome—and of what goes wrong when that choreography breaks down.

Using deep proteogenomic profiling, the team previously found that LIG1 loss robustly correlates with resistance, particularly to platinum-based regimens. The new study digs into the DNA-repair circuitry behind that effect, focusing on how TP53-mutant cells reorganize damage responses when LIG1 is missing.

Early experiments tested whether PARP inhibition alone could reverse the phenotype. In LIG1-loss models, PARP inhibitors such as olaparib showed only modest anti-tumor activity, suggesting that blocking a single repair node is insufficient when repair pathways are rewired downstream of LIG1 deficiency.

The researchers then broadened the hunt by pairing PARP inhibitors with agents that interfere with other DNA damage response pathways. They collaborated with investigators at the Institute of Cancer Research in London to screen PARP inhibitors alongside a larger panel of 120 DNA damage response inhibitors, seeking a combination capable of overcoming the LIG1-loss rewiring.

The most striking result was the synergy between olaparib and ceralasertib, an ATR inhibitor. In TP53-mutant/LIG1-loss cell lines, the dual blockade outperformed either drug alone, and the advantage carried into animal models where tumor growth was reduced.

Mechanistically, the work points to ATR/PARP pathway dependence as a consequence of LIG1 loss under TP53-mutant stress. In other words, the same genetic event that enables chemotherapy resistance also creates a bottleneck in how cells tolerate replication stress and DNA lesions.

Beyond therapy, the study elevates LIG1 status as a practical patient stratification marker. If LIG1 levels are low in a tumor prior to treatment, patients may be more likely to benefit from PARP–ATR combination strategies—turning genomic profiling into a real-time decision tool.

“This Achilles’ heel” framing positions LIG1-loss TNBC as a precision oncology opportunity rather than an unmanageable subtype. With ongoing and future clinical trials, validating LIG1 as a predictive biomarker could refine who gets these therapies and why, accelerating progress for a group with limited options.

Subject of Research: Animals; experimental study
Article Title: LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations
News Publication Date: 15-Jul-2026
Web References: https://aacrjournals.org/mct/article/doi/10.1158/1535-7163.MCT-26-0182/786886/LIG1-Loss-in-TP53-mutant-Triple-Negative-Breast
References: 10.1158/1535-7163.MCT-26-0182
Image Credits:

Keywords: LIG1 loss, TP53 mutations, triple-negative breast cancer, chemotherapy resistance, platinum resistance, DNA repair, PARP inhibition, ATR inhibition, olaparib, ceralasertib, biomarkers, precision oncology